100 results about "Protein antigen" patented technology

The invention discloses a nano antibody targeting GPRC5D as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The nano antibody is generated by mixed immunization of a GPRC5D polypeptide antigen with a sequence shown as SEQ ID NO: 1 and a GPRC5D protein antigen with a sequence shown as SEQ ID NO: 2. The preparation method comprises the following steps: mixing the GPRC5D polypeptide antigen and the GPRC5D protein antigen to immunize alpaca, sampling blood, constructing an antibody library, screening a phage display antibody library, expressing protein, and selecting the nano antibody with the highest affinity. The invention further provides a radionuclide labeled molecular probe, the nano antibody is small in molecular weight and can recognize a large number of epitopes, and the molecular probe prepared from the nano antibody can obtain high-quality images, is used for preparing products for developing multiple myeloma or detecting GPRC5D expression level and has wide application prospects.

This invention relates to compositions (e.g. immunogenic compositions) which can be used to immunise against C. acnes. The compositions comprise C. acnes antigens and antigen combinations, used in the form of nucleic acids (e.g. mRNAs) encoding antigenic proteins or in the form of recombinant protein antigens.

The invention provides a method of preparing a vaccine composition. The method includes infecting gene-edited porcine endogenous retrovirus (PERV) negative swine cells with a microorganism which expresses at least one protein antigen capable of inducing protective immunity in an animal against an infectious agent; culturing the infected cells in culture medium to propagate the microorganism; and harvesting the propagated microorganism from the culture medium to obtain a fraction comprising a PERV free antigen for use in immunizing an animal against the infectious agent.

The invention provides a preparation method and application of a nitrogen-containing heterocyclic micromolecule modified polyethyleneimine polymer derivative. Compared with a polyethyleneimine polymer, the nitrogen heterocyclic ring micromolecule modified polyethyleneimine polymer derivative provided by the invention has immunostimulatory activity. Besides, the polymer derivative material provided by the invention can be simply mixed with a protein antigen to form nanoparticles, so that efficient loading of the protein antigen is realized, the delivery efficiency of the protein antigen to lymph nodes is improved, and the polymer derivative material can be used for preparing a novel nano vaccine preparation.

The invention relates to a novel human immunodeficiency virus envelope protein antigen expressed by mammals. Various embodiments of the invention relate to a polypeptide comprising 1-10 epitopes or more of the HIV envelope protein and a fusion protein, wherein the polypeptide lacks a transmembrane domain of the HIV gp41 protein. Such polypeptides can be expressed in mammalian cells, such as human cells, to produce polypeptides useful, for example, in the development of novel anti-HIV antibodies. The polypeptides described herein and the novel antibodies developed therefrom are generally useful in medical diagnostics, and they can also be used in the prophylactic and therapeutic treatment of HIV.

Disclosed herein are compositions comprising protein antigens and RNA encoding the same (eg., compositions comprising protein antigens and RNA encoding antigens) that can be used to induce an immune response against SARS-CoV-2. Also disclosed herein are immunogenic compositions and medical preparations comprising the same, and methods of making and using the same. In some embodiments, the technologies provided herein can be used to address and / or overcome immune imprinting in SARS-CoV-2.

The invention relates to preparation, epitope identification and application of a PRV TK protein monoclonal antibody. The amino acid sequence of a light chain variable region of the monoclonal antibody is as shown in SEQ ID NO.2, and the amino acid sequence of a heavy chain variable region of the monoclonal antibody is as shown in SEQ ID NO.3. Meanwhile, the invention provides the PRV TK protein antigen epitope peptide, and the specific amino acid sequence of the PRV TK protein antigen epitope peptide is as shown in SEQ ID NO. 4. According to the research, on the basis that the PRV strain TK protein is successfully expressed, the PRV strain TK protein is purified to serve as an antigen to immunize a mouse, the specific monoclonal antibody aiming at the PRV strain TK protein is prepared by utilizing a hybridoma technology, and an important tool is provided for PRV epidemic strain TK protein structure and function research and subsequent establishment of a PRV specific diagnosis method and related research.

The application discloses a method for improving the sensitivity of a porcine circovirus type 2 Cap protein antigen agar diffusion detection, and belongs to the technical field of veterinary products. The method is as follows: (1) inoculating piglets with a porcine circovirus 2a, 2b and 2d trivalent virus-like particle vaccine, and then separating serum to obtain a porcine circovirus 2a, 2b and 2d trivalent high-immune serum; (2) preparing a high-salt agar plate; (3) diluting the trivalent high-immune serum and the porcine circovirus type 2 Cap protein antigen with a high-salt diluent, respectively, and then adding the diluted trivalent high-immune serum and the porcine circovirus type 2 Cap protein antigen into holes of the agar plate, and incubating at 35-37 DEG C for 20-24 h to complete the detection. The application uses high-immune serum and an improved agar diffusion method to quantitatively detect the content of PCV2 Cap protein, and avoids the defects of low tolerance to buffer reagents and poor detection specificity of the commonly used BCA or Bradford protein content detection method.

The filed of the present invention relates to immunotherapeutic peptides, peptide binding agents, and their use, for example, in the immunotherapy of cancer.

The invention discloses a PDCoV-S1 recombinant protein antigen as well as a preparation method and a vaccine thereof, and belongs to the technical field of recombinant protein vaccines. The amino acid sequence of the PDCoV-S1 recombinant protein antigen disclosed by the invention is as shown in SEQ ID NO: 1; the nucleotide sequence of the PDCoV-S1 recombinant protein antigen is as shown in SEQ ID NO: 2. The vaccine provided by the invention only contains recombinant PDCoV-S1 protein and does not contain genetic materials of viruses, so that all risks of virus replication, virulence reversion or gene recombination are fundamentally avoided. Live viruses do not need to be operated in the production process, so that the biological safety risk and the requirement on the production environment are greatly reduced. The constructed stable CHO engineering cell strain is combined with a serum-free suspension culture technology, so that high-density, large-scale and standardized production of the PDCoV-S1 protein can be realized in a bioreactor. The production process is stable and reliable, the batch-to-batch consistency is good, and the uncertainty and volatility caused by the virus culture link of the traditional vaccine are overcome.

The invention discloses a PEDV-S1 recombinant protein antigen as well as a preparation method and a vaccine thereof, and belongs to the technical field of recombinant protein vaccines. The CHO eukaryotic expression system is adopted, high expression and complete glycosylation modification of protein can be achieved, and therefore it is guaranteed that the vaccine has strong immunogenicity; through His tag fusion expression design, nickel column affinity chromatography is conveniently adopted for purification, the process is simple and convenient, and the protein recovery rate is also improved; in combination with a serum-free suspension culture technology, the method is suitable for large-scale production, and the stability among batches is good; the prepared vaccine is high in safety and few in side reaction; an immune challenge test further proves that the vaccine can induce a body to generate a high-level antibody and can effectively protect PEDV attack.

A DMA replication-associated protein (Rep) for multiple sclerosis (MS) is described, wherein (a) an increased amount of Rep protein or fragments thereof in a sample from a subject compared to an amount in a control sample or an increased amount of anti-Rep protein antibodies to antigen in a sample from a subject compared to an amount in a control sample is associated with a diagnosis of MS, wherein the Rep protein is an MSBI1 Rep or MSBI2 Rep.

The invention provides a GP4 protein antigen epitope peptide of PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) and a monoclonal antibody, and provides a hybridoma cell strain for generating the monoclonal antibody, and the preservation number of the hybridoma cell strain is CCTCC (China Center for Type Culture Collection) NO.C2025259. The monoclonal antibody provided by the invention does not react with various other swine viruses such as PCV2, PEDV, GETV and the like, and has good specificity; the polypeptide has good affinity with PRRSV structural protein GP4 at the molecular level and the cellular level, and epitope information is clear. The antibody can significantly inhibit the infection efficiency of a PRRSV-2 JXwn06 strain in MARC-145 cells and alveolar macrophages, has a good PRRSV in-vitro neutralization effect, can be used for developing a high-specificity PRRSV-2 GP4 detection reagent, and is expected to be used as a candidate drug for passive immune prevention and treatment of PRRS.

The present disclosure generally relates to polynucleotide constructs comprising a feline alphaherpesvirus 1 (FeHV-1) genome modified by inserting one or more nucleic acid sequences into the non-coding region between two convergent FeHV-1 genes of the FeHV-1 genome, wherein the one or more nucleic acid sequences encode one or more feline reproductive protein antigens that can stimulate an immune response to reduce the incidence of pregnancy, and uses thereof.

An adjuvant polypeptide, a nano-carrier and application of the nano-carrier in vaccine adjuvant, the present application relates to the field of vaccine.The present application solves the problems of poor antigen compatibility, lack of targeting, low delivery efficiency and insufficient preparation stability of traditional adjuvant.The amino acid sequence of the adjuvant polypeptide Adp is VLGKLAKVAI.The nano-carrier is prepared from the adjuvant polypeptide and antigen.The nano-carrier is prepared by mixing the adjuvant polypeptide and antigen through in-situ radical polymerization.The application of the nano-carrier in vaccine adjuvant.The present application screens a new vaccine adjuvant by bioinformatics method, so that it has the abilities of dendritic cell targeting and intracellular STING pathway activation, thereby enhancing the cross-presentation of antigen.Based on this, the new adjuvant is coupled with monomer, and an intelligent vaccine delivery system is constructed by in-situ polymerization method, so as to realize the efficient delivery of tumor cell membrane protein antigen and improve the immunotherapy effect of tumor vaccine.

The invention belongs to the technical field of biology, and relates to a hybridoma cell strain C8-3-7 and a preparation method thereof. The preservation number of the cell strain C8-3-7 is CCTCC (China Center For Type Culture Collection) No: C202573. The hybridoma cell strain C8-3-7 efficiently expresses the DHX33 antibody and has an infinite proliferation capability. The DHX33 antibody can be specifically combined with DHX33 protein, and can specifically recognize DHX33 protein antigen in ELISA (enzyme-linked immuno sorbent assay) and immunohistochemistry or immunocytochemistry analysis.

The present application belongs to the technical field of nanobody, and particularly relates to an anti-CHI3L1 nanobody, a construction method and application of a phage display library thereof. The present application discloses an anti-CHI3L1 nanobody, which is a nanobody aiming at an epitope of a CHI3L1 protein antigen, and has a VHH chain with an amino acid sequence shown as SEQ ID NO:1. The present application takes CHI3L1 as a research object, immunizes a llama after expression and purification of CHI3L1, and screens an anti-CHI3L1 nanobody by using phage display technology. The nanobody has the ability of high sensitivity and specificity in binding CHI3L1. The anti-CHI3L1 nanobody of the present application provides materials for establishing a diagnostic method and product of CHI3L1, and also provides a research direction for developing a drug for treating a disease related to CHI3L1.

The invention relates to a multi-antigen component PEI lipid delivery system and an anti-avian influenza virus multivalent vaccine comprising the same, belongs to the technical field of biological medicines, and provides a delivery system consisting of PEI, squalene, cholesterol and mPEG. The preparation method comprises the following steps of: constructing mRNA (messenger ribonucleic acid) molecules and a composite vaccine antigen system consisting of prokaryotic expression purified H7N9 avian influenza NP antigen, loading the composite vaccine antigen system into a delivery system to obtain the nanoparticles with a virus-like structure, and displaying the HA protein antigen and the NP antigen in the structure of the nanoparticles in a particle form by the nanoparticles, so that the nanoparticles can be used for preparing the H7N9 avian influenza NP / H7N9 avian influenza NP / H7N9 avian influenza NP / H7N9 avian influenza virus. And the mRNA molecule for coding the NA antigen, which is combined with the mRNA molecule, can be delivered into a cell in a manner of fusing lipid and a cell membrane, so that the mRNA molecule can be effectively expressed to induce a body to generate specific antibody reactions aiming at HA, NA and NP, and the body can also generate specific CTL reactions aiming at HA, NA and NP of different influenza virus strain subtypes.

The application discloses a mycobacterium tuberculosis tandem DNA vaccine W545 and a preparation method and application thereof. The application constructs a novel mycobacterium tuberculosis DNA vaccine W545 with a multi-antigen immune dominant epitope by connecting epitope genes of Ag85A protein and Ag85B protein antigen and Rv1419, Rv3407 and Rv2628c together in series through genetic engineering technology and connecting the epitope genes to a eukaryotic expression vector pVAX1. The prepared mycobacterium tuberculosis tandem DNA vaccine W545 can significantly enhance specific cellular immune function of mice, mainly stimulates Th1 type immune response, and can make the lesion range of organs and tissues of a mouse tuberculosis model significantly reduced and the lesion alleviated in treatment, and can be used in preparation of drugs or vaccines for preventing or treating tuberculosis.

The present application relates to a kind of preparation method and application of HPV recombinant protein therapeutic vaccine, belong to biological medicine technical field, the preparation method of the HPV recombinant protein therapeutic vaccine described includes: a plurality of complex lipid nanoparticles prepared by lipid are simultaneously wrapped and delivered HPV16HPV E6E7 recombinant protein antigen and nucleic acid TLR agonist adjuvant molecule.This application is beneficial to the recombinant protein therapeutic vaccine prepared to induce strong T cell immune response to HPV16E6E7 antigen, kill the cervical cancer cell infected by HPV.In addition, unlike the lipid nanoparticle (LNP) of mRNA vaccine delivery, there is no cation or ionizable lipid in the formula, significantly higher than mRNA vaccine in safety, with greater advantage than mRNA therapeutic vaccine, and low toxicity and side effects, vaccine effect is stable.

The invention provides a universal purification method of a recombinant staphylococcus aureus protein antigen. The purification method comprises the steps of sample treatment and refined purification. Wherein the sample treatment comprises fermentation material liquid crushing, crushed sample clarification and clarified sample concentration; the fine purification comprises primary purification, medium purification and fine purification; the recombinant staphylococcus aureus protein antigen is recombinant staphylococcus aureus enterotoxin A, enterotoxin B, enterotoxin C2 and / or toxic shock syndrome toxin 1. The purification method meets the quality standard required by pharmacopeia, also has the advantages of high yield, simple process, easy amplification and low cost, and greatly simplifies the production and preparation work of the recombinant staphylococcus aureus enterotoxin A, enterotoxin B, enterotoxin C2 and toxic shock syndrome toxin 1.

The present invention relates to compositions (e.g., immunogenic compositions) useful for vaccination against dermatobacterium acnes. These compositions comprise dermatobacterium acnes antigens and combinations of antigens for use in the form of nucleic acids (e.g., mRNA) encoding antigen proteins or in the form of recombinant protein antigens.

The present invention provides an improved RNA construct that enables target cell specific translation of a target protein in eukaryotic cells. The invention employs an RNA construct directly introduced into eukaryotic cells, which is translated into a protein only in the presence of a specific trigger RNA sequence. Controllable expression of protein or any protein antigen in target cells can be achieved, the method is suitable for medical application such as an RNA-based vaccination method, and the antigen can be limited to be expressed in target tissue.

The present application relates to the technical field of biology, and particularly discloses a kind of tyrosine iodination modified PP2A protein monoclonal antibody, preparation method and application.The present application is prepared by tyrosine iodination modified PP2A protein antigen peptide, rabbit is immunized to prepare monoclonal antibody, and is selected by phage display technology, expression vector amplification and ELISA screening, finally obtains a strain of monoclonal antibody R004 that can effectively recognize target.The antibody shows good sensitivity and specificity in immunohistochemistry, cell immunofluorescence and protein immunoblotting.The monoclonal antibody screened in the present application can be used in the detection of tyrosine iodination modification of PP2A protein catalytic subunit 307, and provides support for tumor diagnosis, anti-tumor and neurological disease drug research and development.

The application discloses a double-antibody sandwich ELISA kit for detecting the content of CTHRC1 in blood and a detection method and application thereof, and belongs to the field of molecular biological techniques. In view of the problem that it is difficult to identify early acute aortic dissection at present, a pair of capture antibodies and detection antibodies capable of recognizing different epitopes of CTHRC1 protein antigens are used in the application to assemble a double-antibody sandwich ELISA kit for detecting the content of CTHRC1 in blood. The double-antibody sandwich ELISA kit has high specificity and sensitivity for CTHRC1 protein in serum, can quantitatively detect the CTHRC1 protein in serum, and thus can accurately identify early acute aortic dissection, thereby avoiding misdiagnosis.

The invention provides an antibody pair for detecting the content of main allergen Fed1 of cats, a hybridoma cell of the antibody pair and application of the antibody pair and the hybridoma cell. The antibody pair for detecting the main allergen of the cat is used for preparing mouse hybridoma cells with the preservation numbers of CGMCC (China General Microbiological Culture Collection Center) No.45856 and CGMCC No.45857. The invention also provides a detection reagent for detecting the main allergen Fel d1 of the cat, and the detection reagent comprises a monoclonal antibody FD1.26 which is prepared from mouse hybridoma cells of CGMCC (China General Microbiological Culture Collection Center) No.45857 and is used as a capture antibody, and a monoclonal antibody FD1.25 which is prepared from mouse hybridoma cells of CGMCC No.45856 and is marked with HRP (Horse Radish Peroxidase) and is used as a detection antibody. The detection reagent provided by the invention can specifically recognize and combine with the Fel d 1 protein antigen, and is high in specificity and strong in sensitivity. The kit is used for detecting the cat hair allergen and can be used for accurately, specifically and effectively detecting the cat hair allergen.

To provide a system for unmasking protein antigens and nucleic acid targets from fixed biological samples.SOLUTION: The present disclosure is directed to specimen processing assemblies including (a) a lower plate 10, (b) an upper plate 30 complementary to the lower plate, and (c) a chamber formed therefrom. In some embodiments, the formed chamber is adapted to perform an unmasking operation, e.g., antigen retrieval and / or target retrieval. In some embodiments, the specimen processing assemblies are configured to keep a specimen-bearing substrate 15 horizontal during all processing steps. The present disclosure is also directed to systems including one or more independently operable specimen processing assemblies.SELECTED DRAWING: Figure 14A

The invention relates to the technical field of porcine ileitis detection, and particularly discloses a porcine ileitis antibody detection kit, the kit comprises a colloidal gold immunochromatography test strip, a sample treatment liquid and a negative / positive control, a detection line T line of the test strip is coated with a recombinant Lawsonia intracellularis LsaA protein antigen, a quality control line C line is coated with a goat anti-Protein A antibody, and the detection line C line is coated with a goat anti-Protein A antibody. And the colloidal gold labeling pad is coupled with a Protein A-colloidal gold compound. According to the present invention, the prokaryotically expressed recombinant LsaA antigen is adopted to improve the specificity, the ProteinA is adopted to replace the traditional secondary antibody to simplify the labeling process, the sample treatment liquid formula is optimized to reduce the non-specific reaction, and the HOOK effect is inhibited by adjusting the antigen coating concentration and the marker consumption. Rapid detection of the porcine ileitis antibody is realized, sensitivity and specificity are greatly improved, operation is simple and convenient, professional equipment is not needed, and the problems that an existing detection method is time-consuming, low in sensitivity and high in cost are solved.

The present application belongs to the field of biological pharmacy, and particularly relates to a Helicobacter pylori recombinant protein antigen UreB-s, a preparation method and application thereof. In the preparation of the existing genetic engineering vaccine, the selection of the antigen is very important, and there are problems in screening. Direct use of the original Helicobacter pylori protein often causes unsuccessful recombination expression, or difficult purification or low purity, and the problems of poor immune effect and poor protection, etc. In view of the above problems, the present application provides a Helicobacter pylori recombinant protein antigen UreB-s and a preparation method thereof, which is obtained by E. coli genetic engineering expression. The antigen UreB-s has the advantages of strong hydrophilicity, soluble expression, easy purification, high purity, simple preparation method, etc., has significant economic benefits, and animal experiments prove that it can effectively stimulate the body to produce immune response and has good immune protection effect, and can be used as a vaccine candidate component for preventing Helicobacter pylori infection.

The application relates to preparation, epitope identification and application of a PRV TK protein monoclonal antibody, the amino acid sequence of the light chain variable region of the monoclonal antibody is shown as SEQ ID NO. 2, and the amino acid sequence of the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO. 3. Meanwhile, the application provides a PRV TK protein antigen epitope peptide, and the specific amino acid sequence of the PRV TK protein antigen epitope peptide is shown as SEQ ID NO. 4. On the basis of successfully expressing a PRV strain TK protein, the PRV strain TK protein is purified and used as an antigen to immunize mice, and a hybridoma technology is used to prepare a specific monoclonal antibody for the PRV strain TK protein, so as to provide an important tool for TK protein structure and function research of a PRV epidemic strain, and subsequent establishment of a PRV specific diagnosis method and related research.